Brazilian consensus on the management of bleeding complications related to the use of oral anticoagulants.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lopes Renato Delascio, Silva Pedro Gabriel Melo de Barros E, Furtado Remo Holanda de Mendonça, Macedo Ariane Vieira Scarlatelli, Guerra João Carlos de Campos, Rocha Ana Thereza Cavalcanti, Bizzacch Joyce Maria Annichino, Writing Committee for the SBTH Consensus Collaboration, Executive Committee, Lopes Renato Delascio, Silva Pedro Gabriel Melo de Barros E, Furtado Remo Holanda de Mendonça, Macedo Ariane Vieira Scarlatelli, Guerra João Carlos de Campos, Rocha Ana Thereza Cavalcanti, Bizzacch Joyce Maria Annichino, Collaborators, Freitas Alexandre Coutinho Teixeira de, Moraes Antonio Carlos da Silva, Batista Bernardo Pinheiro de Senna Nogueira, Poncinelli Christiane Soares, Campos Fábio Guilherme Caserta Maryssael de, Azi Liana Maria Tôrres de Araujo, Silva Lucas Oliveira Junqueira E, Franco Luciana Ferreira, Alves Maramelia Miranda, Goldbaum Mauro, Caponero Ricardo, Pavanello Ricardo, Passos Rogerio da Hora, Fernandes Roni de Carvalho, Martins Sheila, Rezende Suely Meireles, Crochemore Tomaz, Campagnucci Valquíria Pelisser, Barros Venina Isabel Poço Viana Leme de
Аннотация
METHODS: This Brazilian multidisciplinary consensus was developed by the Brazilian Society of Thrombosis and Hemostasis (SBTH) based on contemporary international guidelines and the best available scientific evidence. Recommendations were reviewed by a multidisciplinary panel of experts and adapted to the Brazilian clinical setting and local resource availability.
RESULTS: The document proposes a structured stepwise approach for the management of oral anticoagulation-related bleeding, including initial stabilization, bleeding severity assessment, laboratory evaluation, temporary interruption of anticoagulation, and indication of reversal or hemostatic therapies in patients with major bleeding and significant circulating anticoagulant levels. Specific management strategies are detailed according to anticoagulant class, including idarucizumab for dabigatran and andexanet alfa or prothrombin complex concentrates for factor Xa inhibitors. The consensus also emphasizes multidisciplinary follow-up and individualized decision-making regarding anticoagulation resumption after bleeding control.
CONCLUSION: Management of bleeding in patients receiving oral anticoagulants requires rapid clinical assessment, severity stratification, targeted reversal strategies, and multidisciplinary care. Individualized reassessment of thrombotic versus hemorrhagic risk is essential to optimize outcomes and guide safe reintroduction of anticoagulation therapy after bleeding resolution.